Post-Transplant Low-Dose Azacitidine Can Improve Overall Survival in AML/MDS Patients and Is Associated With Decrease Risks of Severe Acute and Chronic GVHD
Biology of Blood and Marrow Transplantation- Netherlands
doi 10.1016/j.bbmt.2017.12.383
Full Text
Abstract
Available in
Date
March 1, 2018
Authors
Publisher
Elsevier BV